Adjuvant oophorectomy versus CMF in premenopausal node-positive breast cancer: long-term results of an experience at the Milan Cancer Institute
Salvadori, B.; Celio, L.; Oriana, R.; Bajetta, E.
Tumori 86(3): 258-259
2000
ISSN/ISBN: 0300-8916 PMID: 10939610 Document Number: 516836
Document emailed within 1 workday
Related Documents
Taguchi, T.; Koyama, H.; Yayoi, K.; Wada, T.; Takatsuka, Y.; Sonoo, H.; Morimoto, K.; Tominaga, T.; Abe, R.; Enomoto, K. 1995: Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 495-508Tancini, G.; Bajetta, E.; Marchini, S.; Valagussa, P.; Bonadonna, G.; Veronesi, U. 1979: Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer Cancer Clinical Trials 2(4): 285-292
Crivellari, D. 2002: Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group Tumori 88(1 Suppl. 1): S81-S82
Sutepvarnon, A.; Warnnissorn, M.; Srimuninnimit, V. 2013: Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer Journal of the Medical Association of Thailand 96(Suppl 2): S60-S66
Saimura, M.; Mitsuyama, S.; Anan, K.; Tanaka, M.; Shimada, K.; Hirose, N.; Ogawa, S.; Tamaki, N.; Tomisaki, S.; Tamura, K. 2008: Adjuvant epirubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(9): 1519-1523
Spigel, D.R.; Hainsworth, J.D.; Burris, H.A.; Molthrop, D.C.; Peacock, N.; Kommor, M.; Vazquez, E.R.; Greco, F.A.; Yardley, D.A. 2011: A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer Clinical Advances in Hematology and Oncology: H&o 9(4): 280-286
Kurebayashi, J. 2006: Postoperative adjuvant therapy for premenopausal patients with breast cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 64(10): 1963-1969
Sun, X.; Liu, J-Juan.; Wang, Y-Sheng.; Song, X-Rang.; Zhong, W-Xia.; Zhou, C-Chun.; Mu, D-Bin.; Zuo, W-Shu.; Yu, Z-Yong.; Zhou, Z-Bo. 2011: Using intra-operative GeneSearchTM Breast Lymph Node Assay to detect breast cancer metastases in sentinel lymph nodes: results from a single institute in China Chinese Medical Journal 124(7): 973-977
Marshall, J.S.; Gordon, N.H.; Hubay, C.A.; Pearson, O.H. 1987: Assessment of tamoxifen as adjuvant therapy in stage Ii breast cancer: a long-term follow-up Journal of Laboratory and Clinical Medicine 109(3): 300-307
Rudan, I.; Skorić, T.; Rudan, N. 1994: Breast cancer prognosis. II. Prognostic factors in patients with node-positive (N1-3) breast cancer Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 48(4-5): 165-170
Sajjinanont, T.; Rajchadara, S.; Sriassawaamorn, N.; Panichkul, S. 2005: The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women Journal of the Medical Association of Thailand 88(Suppl 3): S71-S76
Fortunato, L.; Drago, S.; Vitelli, C.E.; Santoni, M.; Gucciardo, G.; Cabassi, A.; Farina, M.; La Pinta, M.; Remedi, M.; Pagano, G.; Silipod, T.; Terribile, D.; Stagnitto, D.; Grassi, G.B. 2006: Sentinel lymph node biopsy in breast cancer. Experience of the Rome Breast Cancer Study Group Chirurgia Italiana 58(6): 689-696
Gangi, A.; Essner, R.; Giuliano, A.E. 2014: Long-term clinical impact of sentinel lymph node biopsy in breast cancer and cutaneous melanoma Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 58(2): 95-104
Wang, Y.; Yao, L.; Liu, Y.-q.; Xu, Y.; Ou, Y.-t.; Li, J.-f.; Wang, T.-f.; Fan, Z.-q.; Fan, T.; Lin, B.-y.; Xie, Y.-t. 2010: Different influence of Her-2 expression on the prognosis in node-positive and node-negative breast cancer Zhonghua Zhong Liu Za Zhi 32(7): 511-514
Iwata, H.; Miura, S. 2002: Axillary lymph node dissection in clinically node-positive breast cancer Nihon Geka Gakkai Zasshi 103(11): 831-834
Neoral, C.; Král, V.; Aujeský, R.; Bohanes, T. 2000: Possibilities of positive affection of long-term results in patients with esophageal cancer Acta Universitatis Palackianae Olomucensis Facultatis Medicae 143: 97
Roumen, R.M. 2000: Prognostic benefits evaluated: new guidelines for systemic adjuvant therapy for axillary node-negative breast cancer vs. implementation of sentinel node biopsy procedure Nederlands Tijdschrift Voor Geneeskunde 144(21): 980-984
Horiguchi, J.; Oyama, T.; Takata, D.; Rokutanda, N.; Nagaoka, R.; Odawara, H.; Tokiniwa, H.; Tozuka, K.; Kikuchi, M.; Sato, A.; Takeyoshi, I. 2011: Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience Anticancer Research 31(9): 3041-3046
Merkel, D.E.; Osborne, C.K. 1989: Adjuvant treatment of node-negative breast cancer Texas Medicine 85(1): 32-36
Yoshioka, S.; Hojo, S.; Toyoda, Y.; Noma, T.; Matsunaga, H.; Miyagaki, H.; Nishida, H.; Shingai, T.; Fukunaga, H.; Fukuzaki, T.; Ohigashi, H.; Maeura, Y. 2014: Locoregional recurrence of HER2-positive breast cancer - treatment after complete remission and long-term clinical benefits Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1924-1926